|
2014 Journal Article Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometryAdams, Rebecca L. C., Cheung, Catherine, Banh, Raymond, Saal, Russell, Cross, Donna, Gill, Devinder, Self, Marlene, Klein, Kerenaftali and Mollee, Peter (2014). Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. Cytometry Part B - Clinical Cytometry, 86 (2), 80-90. doi: 10.1002/cyto.b.21138 |
|
2013 Journal Article Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosisMollee, Peter, Tate, Jill and Pretorius, Carel J. (2013). Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clinical Chemistry and Laboratory Medicine, 51 (12), 2303-2310. doi: 10.1515/cclm-2013-0361 |
|
2013 Journal Article Towards improved measurement of serum free light chains: clinical and laboratory issuesTate, Jill and Mollee, Peter (2013). Towards improved measurement of serum free light chains: clinical and laboratory issues. Biochimica Clinica, 37 (5), 395-404. |
|
2013 Journal Article CD62L as a therapeutic target in chronic lymphocytic leukemiaBurgess, Melinda, Gill, Devinder, Singhania, Richa, Cheung, Catherine, Chambers, Lynne, Renyolds, Brent A., Smith, Louise, Mollee, Peter, Saunders, Nicholas and McMillan, Nigel A. J. (2013). CD62L as a therapeutic target in chronic lymphocytic leukemia. Clinical Cancer Research, 19 (20), 5675-5685. doi: 10.1158/1078-0432.CCR-13-1037 |
|
2013 Journal Article Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survivalJackson, K., Mollee, P., Morris, K. and Kennedy, G. (2013). Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival. Internal Medicine Journal, 43 (8), 953-954. doi: 10.1111/imj.12218 |
|
2013 Journal Article Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospitalSolano, Connie, Mutsando, Howard, Self, Marlene, Morel-Kopp, Marie-Christine and Mollee, Peter (2013). Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital. Blood Coagulation & Fibrinolysis, 24 (4), 365-370. doi: 10.1097/MBC.0b013e32835cc17e |
|
2013 Journal Article Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unitJackson, Kathryn, Mollee, Peter, Morris, Kirk, Butler, Jason, Jackson, Dwane, Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen (2013). Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. Leukemia and Lymphoma, 55 (1), 97-104. doi: 10.3109/10428194.2013.796045 |
|
2012 Journal Article CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitroBurgess, Melinda, Cheung, Catherine, Chambers, Lynne, Ravindranath, Karunya, Minhas, Gunjeet, Knop, Louise, Mollee, Peter, McMillan, Nigel A. J. and Gill, Devinder (2012). CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leukemia and Lymphoma, 53 (10), 1988-1998. doi: 10.3109/10428194.2012.672735 |
|
2012 Journal Article Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphomaKeane, C., Nourse, J. P., Crooks, P., Nguyen-Van, D., Mutsando, H., Mollee, P., Lea, R. A. and Gandhi, M. K. (2012). Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Internal Medicine Journal, 42 (10), 1113-1119. doi: 10.1111/j.1445-5994.2011.02587.x |
|
2012 Journal Article Gamma-delta T-cell lymphoma with CNS involvement presenting with proptosis: A case study workup, treatment and prognosisSugnanam, K., Ooi, L., Mollee, P. and Vu, P. (2012). Gamma-delta T-cell lymphoma with CNS involvement presenting with proptosis: A case study workup, treatment and prognosis. Orbit, 31 (5), 364-366. doi: 10.3109/01676830.2012.711411 |
|
2012 Journal Article Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activityLane, Steven, Gill, Devinder, McMillan, Nigel A. J., Saunders, Nicholas, Murphy, Rachel, Spurr, Terrence, Keane, Colm, Fan, Helen Mar and Mollee, Peter (2012). Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia & Lymphoma, 53 (6), 1077-1083. doi: 10.3109/10428194.2011.642302 |
|
2012 Journal Article A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosisMollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, H.Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy, Fan, Helen Mar and Gill, Devinder S. (2012). A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. British Journal of Haematology, 157 (6), 766-769. doi: 10.1111/j.1365-2141.2012.09080.x |
|
2012 Journal Article Continuous lenalidomide treatment for newly diagnosed multiple myelomaPalumbo, Antonio, Hajek, Roman, Delforge, Michel, Kropff, Martin, Petrucci, Maria Teresa, Catalano, John, Gisslinger, Heinz, Wiktor-Jędrzejczak, Wiesław, Zodelava, Mamia, Weisel, Katja, Cascavilla, Nicola, Iosava, Genadi, Cavo, Michele, Kloczko, Janusz, Bladé, Joan, Beksac, Meral, Spicka, Ivan, Plesner, Torben, Radke, Joergen, Langer, Christian, Ben Yehuda, Dina, Corso, Alessandro, Herbein, Lindsay, Yu, Zhinuan, Mei, Jay, Jacques, Christian, Dimopoulos, Meletios A., MM-015 Investigators and Mollee, Peter (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England Journal of Medicine, 366 (19), 1759-1769. doi: 10.1056/NEJMoa1112704 |
|
2012 Journal Article Recommendations for standardized reporting of protein electrophoresis in Australia and New ZealandTate, Jillian, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard, Wienholt, Louise and Mollee, Peter (2012). Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 49 (3), 242-256. doi: 10.1258/acb.2011.011158 |
|
2012 Journal Article WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidationGray, James X., McMillen, Lyle, Mollee, Peter, Paul, Sanjoy, Lane, Steven, Bird, Robert, Gill, Devinder, Saal, Russell and Marlton, Paula (2012). WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leukemia Research, 36 (4), 453-458. doi: 10.1016/j.leukres.2011.09.005 |
|
2012 Journal Article Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian studyMorel-Kopp, Marie-Christine, Tan, Chee Wee, Brighton, Timothy A., McRae, Simon, Baker, Ross, Huyen Tran, Mollee, Peter, Kershaw, Geoffrey, Joseph, Joanne and Ward, Christopher (2012). Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thrombosis and Haemostasis, 107 (3), 575-583. doi: 10.1160/TH11-09-0631 |
|
2012 Journal Article Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trialTrappe, Ralf, Oertel, Stephan, Leblond, Veronique, Mollee, Peter, Sender, Monica, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Horst, Heinz August, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Leithäuser, Malte, Zimmermann, Heiner, Anagnostopoulos, Ioannis, Raphael, Martine, Riess, Hanno, Choquet, Sylvain and for the German PTLD Study Group and the European PTLD Network (2012). Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. The Lancet Oncology, 13 (2), 196-206. doi: 10.1016/S1470-2045(11)70300-X |
|
2012 Journal Article High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal diseaseMutsando, Howard, Fahim, Magid, Gill, Devinder S., Hawley, Carmel M., Johnson, David W., Maher, K. Gandhi, Marlton, Paula V., Mar Fan, Helen G. and Mollee, Peter N. (2012). High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. American Journal of Blood Research, 2 (1), 66-70. |
|
2011 Journal Article Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopesNguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159. |
|
2011 Journal Article Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trialCoiffier, Bertrand, Osmanov, Evgenii A., Hong, Xiaonan, Scheliga, Adriana, Mayer, Jiri, Offner, Fritz, Rule, Simon, Teixeira, Adriana, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Esseltine, Dixie-Lee, Zhu, Eugene, Enny, Christopher, Theocharous, Panteli, van de Velde, Helgi, Elsayed, Yusri A., Zinzani, Pier Luigi, LYM-3001 study investigators and Mollee, Peter (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology, 12 (8), 773-84. doi: 10.1016/S1470-2045(11)70150-4 |
